First Head-to-Head Trial of a TNF Inhibitor Versus Methotrexate Monotherapy in Psoriatic Arthritis Shows ENBREL ® (Etanercept) Monotherapy and Combination Therapy Both Superior to Methotrexate
Results From Head-To-Head Phase 3 SEAM-PsA Study Assessing ENBREL and Methotrexate Regimens in Patients With Psoriatic Arthritis Presented at 2018 ACR/ARHP Annual Meeting Additional Phase 3b Results Show Modified ENBREL Formulation Associated With Significantly Lower Mean Injection Site Pain Versus Prior Formulation Data Presentations Result of Continued Dedication to Evaluate Optimal Use of ENBREL THOUSAND OAKS, Calif., Oct. 24, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that positive results from the Phase 3 SEAM-PsA study comparing the efficacy of Enbrel® (etanercept) monotherapy and ENBREL pl...
Source: Amgen News Release - October 24, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Bringing Hollywood to Medtech
Typically, the tutorials for medical devices aren’t extremely flashy. The videos convey a simple message and get straight to the point. However, one company is bringing high quality production levels to the medtech industry. Spotburner is a specialist in producing videos for healthcare companies. “I have a television studio and I have been producing commercials for about 20 years,” Bob Bekian, CEO of Spotburner told MD+DI. “Typically, these sort of productions (medical device videos) have been a must-do, but they haven’t been able to ...
Source: MDDI - July 27, 2018 Category: Medical Devices Authors: Omar Ford Tags: Regulatory and Compliance Source Type: news

Biocon puts arthritis drug on backburner
Biocon and Mylan have been working for a decade on a biosimilar version of the drug, originally sold by Amgen under brand name Enbrel. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 11, 2018 Category: Pharmaceuticals Source Type: news

Lupin and Mylan Partner to Commercialize Enbrel(R) (Etanercept) Biosimilar
MUMBAI, India and HERTFORDSHIRE, England and PITTSBURGH, June 28, 2018 -- (Healthcare Sales & Marketing Network) -- Pharma major Lupin Limited (Lupin) and global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that the two companies will p... Biopharmaceuticals, Generics Mylan, Lupin, biosimilar, Enbrel, etanercept (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 28, 2018 Category: Pharmaceuticals Source Type: news

Lupin-Mylan team up for biosimilar Etanercept
Under the terms of the agreement, Lupin will receive an up-front payment of $15 million and potential commercial milestones together with an equal share in net profits of the product. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 28, 2018 Category: Pharmaceuticals Source Type: news

Lupin, Nichi-Iko tie up for commercialization of biosimilar Etanercept in Japan
Mumbai based Lupin pharma and Japan's Nichi-Iko have tied up for the distribution, promotion and sale of Lupin ’s recently-filed biosimilar Etanercept in Japan. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 18, 2018 Category: Pharmaceuticals Source Type: news

Novartis touts effectiveness, safety of autoimmune drug copies
ZURICH (Reuters) - Novartis on Friday touted safety and efficacy of its biosimilar copies of Johnson& Johnson's Remicade and Amgen Inc's Enbrel, citing a study it hopes will help convince doctors that switching from the original medicines is a viable alternative for treating autoimmune diseases. (Source: Reuters: Health)
Source: Reuters: Health - June 15, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Psoriasis Drugs Strike Immune Targets (Raptiva, Enbrel)
Title: Psoriasis Drugs Strike Immune Targets (Raptiva, Enbrel)Category: Doctor's& Expert's views on SymptomsCreated: 11/20/2003 12:00:00 AMLast Editorial Review: 6/13/2018 2:55:08 PM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - June 13, 2018 Category: Dermatology Source Type: news

Low Doses of Etanercept to Maintain Remission in PsA Low Doses of Etanercept to Maintain Remission in PsA
Find out how psoriatic arthritis patients who have achieved sustained remission with etanercept may benefit from a dosing interval increase.Journal of Clinical Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 23, 2018 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Finding Good Candidates for Risk-Sharing Arrangements
Continued from Part I that discusses the tools device manufacturers can use to manage risk How to find good candidates? Not all devices are created equal. But how can device manufacturers identify the low-hanging fruit for a risk-sharing arrangement? Needless to say, the more characteristics a product has that are associated with successful risk-sharing arrangements, the more such an arrangement is likely to succeed. To illustrate, in Exhibit 1, we chart a select number of risk-sharing arrangements established since 2015 along two key dimensions: product effectiveness and time needed to observe expected outcomes. The findi...
Source: MDDI - April 3, 2018 Category: Medical Devices Authors: Harry Liu and Christine Chen Tags: Contract Manufacturing Design Source Type: news

Etanercept Biosimilar Is Effective, Well-tolerated for Rheumatoid Arthritis Etanercept Biosimilar Is Effective, Well-tolerated for Rheumatoid Arthritis
The biosimilar LBEC0101 is equivalent to etanercept (Enbrel) in treating patients with rheumatoid arthritis (RA) who respond inadequately to methotrexate, according to researchers from Korea and Japan.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - February 20, 2018 Category: Orthopaedics Tags: Rheumatology News Source Type: news

Factors ID'd That Predict RA Remission with Etanercept (CME/CE)
(MedPage Today) -- Leaner patients with less active disease most likely to show strong response (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - January 21, 2018 Category: Primary Care Source Type: news

Biological Therapies and Improvements in QoL in Psoriasis Biological Therapies and Improvements in QoL in Psoriasis
This study compared the effectiveness of adalimumab, etanercept and ustekinumab on improvements in HRQoL in patients with psoriasis. What factors are associated with these improvements?The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 16, 2018 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Etanercept, Tocilizumab and Interleukin-1 Inhibitors in JIA Etanercept, Tocilizumab and Interleukin-1 Inhibitors in JIA
What do we currently know about the efficacy and safety of these biologic agents in the treatment of systemic onset juvenile idiopathic arthritis?Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 16, 2018 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Arthritis Drugs Show How US Drug Prices Defy Economics Arthritis Drugs Show How US Drug Prices Defy Economics
Wholesale prices for Humira and Enbrel, the two most commonly used treatments for rheumatoid arthritis, known as RA, increased more than 70 percent in the past three years.Kaiser Health News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 28, 2017 Category: Consumer Health News Tags: Rheumatology News Source Type: news

A repurposed drug could open door to more stem cell transplants
(University of British Columbia) Etanercept, a drug used to treat arthritis and psoriasis, boosted the survival of blood stem cells in a mouse model. The findings provide a strong basis for a clinical trial to see whether etanercept or a similar drug would improve outcomes for people receiving blood stem cell transplants. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 20, 2017 Category: Cancer & Oncology Source Type: news

Erelzi (etanercept-szzs Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 19, 2017 Category: Drugs & Pharmacology Source Type: news

Amgen launches Enbrel Mini single-dose cartridges with reusable auto-injector
Amgen (NSDQ:AMGN) announced today the U.S. launch of its Enbrel Mini single-dose prefilled cartridges delivered using its reusable AutoTouch auto-injector. The drug-device combination was designed with a needle that stays hidden during injection and a sensor to detect placement on the skin. Get the full story at our sister site, Drug Delivery Business News. The post Amgen launches Enbrel Mini single-dose cartridges with reusable auto-injector appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - November 17, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Orthopedics Pharmaceuticals Wall Street Beat Amgen Source Type: news

Amgen Launches The ENBREL Mini(TM) Single-Dose Prefilled Cartridge With AutoTouch(TM) Reusable Autoinjector That Is Ergonomically Designed For Patients
Innovative Reusable Autoinjector Provides Additional Administration Option for Enbrel® (Etanercept) Users Awarded Arthritis Foundation Ease of Use (SM) Commendation THOUSAND OAKS, Calif., Nov. 17, 2017 -- (Healthcare Sales & Marketing Network) -... Biopharmaceuticals, Devices, Drug Delivery, Product Launch Amgen, ENBREL Mini, Enbrel, Etanercept, autoinjector (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 17, 2017 Category: Pharmaceuticals Source Type: news

Amgen Launches The ENBREL Mini ™ Single-Dose Prefilled Cartridge With AutoTouch™ Reusable Autoinjector That Is Ergonomically Designed For Patients
Innovative Reusable Autoinjector Provides Additional Administration Option for Enbrel® (Etanercept) Users Awarded Arthritis Foundation Ease of Use (SM) Commendation THOUSAND OAKS, Calif., Nov. 17, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced that the ENBREL Mini™ with AutoTouch™ is now available in the United States (U.S.). Awarded the Arthritis Foundation Ease of UseSM Commendation, this new and innovative delivery system provides an additional administration option for appropriate ENBREL patients. The AutoTouch™ reusable autoinjector has an ergonomic design that includes feature...
Source: Amgen News Release - November 17, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Patients' drugs fail to arrive  at their homes
The 42-year-old teacher has ankylosing spondylitis — a type of inflammatory arthritis which mainly affects the spine — and has been treating it with injections of etanercept since 2009. (Source: the Mail online | Health)
Source: the Mail online | Health - November 14, 2017 Category: Consumer Health News Source Type: news

The patients left in despair as drugs fail to arrive  
The 42-year-old teacher has ankylosing spondylitis — a type of inflammatory arthritis which mainly affects the spine — and has been treating it with injections of etanercept since 2009. (Source: the Mail online | Health)
Source: the Mail online | Health - November 14, 2017 Category: Consumer Health News Source Type: news

Godly gift for arthritis pain
Big Pharma is at it again… Creating and selling a drug that causes thousands of heart attacks and strokes each year. In 2015, the FDA asked drug makers to strengthen their warning labels. Since then, most have listed their dangerous side effects on the bottle. But one manufacturer thought they didn’t have to warn people about their dangerous drug. They marketed their product as a “unique” breakthrough. They even published studies promising it was “safe for long-term use.” 1 The drug is a 7-year-old arthritis drug called Actemra. It’s made by the Swiss pharmaceutical company Roche....
Source: Al Sears, MD Natural Remedies - October 5, 2017 Category: Complementary Medicine Authors: Al Sears Tags: Anti-Aging Source Type: news

MRI Shows Bone Repair in Treated Spine Disease (CME/CE)
(MedPage Today) -- Structural lesions improved with etanercept in nonradiographic axial spondyloarthritis (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - October 2, 2017 Category: Primary Care Source Type: news

Sandoz ’s Erelzi available for multiple inflammatory disease treatment in Canada
Novartis division Sandoz has made its Erelzi (etanercept) therapy available for the treatment of multiple inflammatory diseases for patients in Canada. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 21, 2017 Category: Pharmaceuticals Source Type: news

Pfizer revenue misses on lower Prevnar, Enbrel sales
(Reuters) - Pfizer Inc reported quarterly revenue on Tuesday that missed Wall Street estimates, driven by lower demand for its rheumatoid arthritis treatment Enbrel and pneumonia vaccine Prevnar. (Source: Reuters: Health)
Source: Reuters: Health - August 1, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Pfizer quarterly revenue slips 2 percent
(Reuters) - Pfizer Inc reported a nearly 2 percent drop in quarterly revenue on Tuesday, driven by lower demand for its rheumatoid arthritis treatment Enbrel and pneumonia vaccine Prevnar. (Source: Reuters: Health)
Source: Reuters: Health - August 1, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Saving Vanessa, part 1: A mystery rash, a stroke and an epic rescue
Vanessa’s rash first appeared on her arms and legs when she 3 or 4 months old. It was red and bumpy and went away when she was sick with a virus, which happened often. Then it would come back. The dermatology team she saw at Boston Children’s Hospital was puzzled. “I was expecting they were going to think it was nothing, but they took it very seriously,” says Katherine Bell, one of Vanessa’s mothers. “They took a biopsy and very quickly realized they had no idea what it was.” Vanessa’s case was even featured at a regional dermatology conference where doctors take up mystery p...
Source: Thrive, Children's Hospital Boston - July 25, 2017 Category: Pediatrics Authors: Nancy Fliesler Tags: Diseases & Conditions Our Patients’ Stories Dr. Carolyn Rogers Dr. Pui Lee Dr. Robert Sundel Dr. Scellig Stone Dr. Todd Lyons stroke Source Type: news

Novartis unit Alcon posts modest Q2 gain
(Reuters) — Long-suffering Novartis (NYSE:NVS) unit Alcon‘s sales growth accelerated in the second quarter, boosting options for the business including a possible disposal, CEO Joe Jimenez said today. The eye care subsidiary’s sales rose 1% to $1.5 billion, including intraocular lens revenues, which grew for the first time in the second quarter since 2014. Spending continued to promote products with eye surgeons, resulting in a $19 million operating loss. Novartis has been reviewing Alcon for a possible disposal, with an update slated for this year. All options are under consideration, Jimenez reiter...
Source: Mass Device - July 18, 2017 Category: Medical Devices Authors: Brad Perriello Tags: MassDevice Earnings Roundup Mergers & Acquisitions Optical/Ophthalmic Wall Street Beat Alcon Novartis Source Type: news

Novartis gets European OK for biosimilar of Amgen's Enbrel
ZURICH (Reuters) - Novartis's generics unit Sandoz said the European Commission approved Erelzi, its biosimilar to Amgen's Enbrel, to treat inflammatory diseases such as rheumatoid arthritis, psoriasis, and psoriatic arthritis. (Source: Reuters: Health)
Source: Reuters: Health - June 27, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

In Rheumatoid Arthritis, Adding a Biologic Agent Before Trying Triple Therapy Likely Not Cost-Effective (FREE)
By Amy Orciari Herman Edited by David G. Fairchild, MD, MPH For patients with active rheumatoid arthritis despite methotrexate therapy, adding a biologic agent (e.g., etanercept) before trying triple therapy would lead to substantial cost increases without much … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - May 30, 2017 Category: Primary Care Source Type: news

Cost controls help offset lower Amgen first-quarter drug sales
(Reuters) - Amgen Inc on Wednesday reported higher-than-expected first-quarter profit as cost controls helped offset a sharp drop in sales of Enbrel, its blockbuster rheumatoid arthritis and psoriasis drug. (Source: Reuters: Health)
Source: Reuters: Health - April 26, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Your NEJM Group Today: Histology Rings True / Probiotics for C. diff / Illinois IM Opportunity (FREE)
By the Editors Here's today's offering from NEJM Group:NEJM Clinical Practice Center: Clinical Problem-Solving: A 58-year-old man with nonerosive rheumatoid arthritis who was being treated with etanercept … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - March 6, 2017 Category: Primary Care Source Type: news

Amgen Reports Fourth Quarter And Full Year 2016 Financial Results
THOUSAND OAKS, Calif., Feb. 2, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2016. Key results include: For the fourth quarter, total revenues increased 8 percent versus the fourth quarter of 2015 to $6.0 billion. Product sales grew 6 percent driven by Enbrel® (etanercept), Prolia® (denosumab), Repatha® (evolocumab) and KYPROLIS® (carfilzomib). For the full year, total revenues increased 6 percent to $23.0 billion, with 5 percent product sales growth. GAAP earnings per share (EPS) increased 9 percent in the fourth ...
Source: Amgen News Release - February 2, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Novartis says court battle will delay its Enbrel copy until 2018 at least
ZURICH (Reuters) - The Novartis copy of Amgen's blockbuster psoriasis drug Enbrel will not go on sale before 2018 at the earliest because of the U.S. company's patent protection challenge, the Swiss drugmaker's head of generics told Reuters. (Source: Reuters: Health)
Source: Reuters: Health - January 25, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Slight, Nonsignificant CV Risk with Actemra vs Enbrel
(MedPage Today) -- Few events seen with either agent (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - November 29, 2016 Category: Journals (General) Source Type: news

Enbrel (Etanercept) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 18, 2016 Category: Drugs & Pharmacology Source Type: news

Actemra Carries Slight Increase in Heart Risk vs. Enbrel
(MedPage Today) -- But efficacy, too, must be weighed in treatment decisions (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - November 17, 2016 Category: Cardiology Source Type: news

FDA OKs Etanercept (Enbrel) for Kids With Plaque Psoriasis FDA OKs Etanercept (Enbrel) for Kids With Plaque Psoriasis
Etanercept becomes the first biologic approved for children aged 4 years and older with moderate-to-severe plaque psoriasis.FDA Approvals (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - November 8, 2016 Category: Dermatology Tags: Dermatology News Alert Source Type: news

Data To Be Presented At ACR/ARHP 2016 Annual Meeting Show Amgen's Ongoing Commitment To Therapies For Patients With Serious Inflammatory And Bone Diseases
21 Abstracts to be Featured Provide Real-World and Disease State Insights, Highlight Clinical and Health Economic Impact of Rheumatologic Diseases and Osteoporosis THOUSAND OAKS, Calif., Nov. 7, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will present data from multiple studies related to Enbrel® (etanercept), Prolia® (denosumab) and AMJEVITA™ (adalimumab-atto), as well as investigational candidates, including ABP 710 (infliximab biosimilar candidate) and romosozumab, at the American College of Rheumatology (ACR) and Association of Rheumatology Health Professionals (ARHP) Annual...
Source: Amgen News Release - November 7, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

FDA Approves Expanded Use Of ENBREL ® (etanercept) To Treat Children With Chronic Moderate-To-Severe Plaque Psoriasis
First and Only Systemic Drug Approved in the U.S. to Treat Children Affected by This Serious Inflammatory Disease THOUSAND OAKS, Calif., Nov. 4, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the expanded use of ENBREL® (etanercept), making it the first and only systemic therapy to treat pediatric patients (ages 4-17) with chronic moderate-to-severe plaque psoriasis. "As many parents of children with moderate-to-severe plaque psoriasis can tell you, there is a n...
Source: Amgen News Release - November 4, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

FDA Approves Expanded Use of Enbrel (etanercept) to Treat Children with Chronic Moderate-To-Severe Plaque Psoriasis
THOUSAND OAKS, Calif., Nov. 4, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the expanded use of Enbrel (etanercept),... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 4, 2016 Category: Drugs & Pharmacology Source Type: news

Erelzi (etanercept-szzs) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 12, 2016 Category: Drugs & Pharmacology Source Type: news

A Push to Lower Drug Prices That Hit Insurers and Employers the Hardest
Seeking to force drug price competition in an expensive category, the company wants insurers to cover fewer anti-inflammatory drugs, at least as a first-line treatment. (Source: NYT Health)
Source: NYT Health - September 8, 2016 Category: Consumer Health News Authors: KATIE THOMAS Tags: Express Scripts Inc Drugs (Pharmaceuticals) Health Insurance and Managed Care Prices (Fares, Fees and Rates) Enbrel (Drug) Humira Source Type: news

New Version of RA Drug Enbrel: FAQ
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - September 2, 2016 Category: Journals (General) Source Type: news

New Version of RA Drug Enbrel: FAQ
Title: New Version of RA Drug Enbrel: FAQCategory: Health NewsCreated: 9/2/2016 12:00:00 AMLast Editorial Review: 9/2/2016 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - September 2, 2016 Category: Rheumatology Source Type: news

New Version of RA Drug Enbrel: FAQ
The FDA cleared the way for what is hoped may be a more affordable version of the popular arthritis drug Enbrel. Tuesday the agency approved Erelzi (etanercept-szzs), a "biosimilar" to Enbrel. (Source: WebMD Health)
Source: WebMD Health - September 1, 2016 Category: Consumer Health News Source Type: news

Monthly News Roundup - August 2016
FDA Approves Erelzi: Sandoz ’s Biosimilar For Enbrel A third U.S. biosimilar has been FDA-approved; this time it’s Erelzi (etanercept-szzs), a biosimilar to Amgen’s tumor necrosis factor (TNF) blocker Enbrel. Sandoz’s Erelzi is the first... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 31, 2016 Category: Pharmaceuticals Source Type: news

FDA Approves New Biological Drug for RA
Erelzi is a biosimilar for Enbrel (Source: WebMD Health)
Source: WebMD Health - August 31, 2016 Category: Consumer Health News Source Type: news